HuagongsheHuagongshe Chemistry Print Report · For research reference only
N-methyl-1-(propan-2-yl)piperidin-4-amine → 1-isopropyl-N-methyl-N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-amine
Participants
| Role | Name | HCID | Charge |
|---|---|---|---|
| Reactant | N-methyl-1-(propan-2-yl)piperidin-4-amine | HCID 3159676 | — |
| Reactant | 4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine | HCID 59605812 | — |
| Product | 1-isopropyl-N-methyl-N-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-amine | HCID 59605217 | — |
Reaction Steps
4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine (50 mg) was reacted with 1-isopropyl-N-methylpiperidin-4-amine via General Procedure E to give 22.1 mg of 295 following reverse phase purification. MS (Q1) 518.3 (M)+
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| Patent number | US08394796B2 |
| Source dataset | uspto-grants-2013_03 |
| ORD ID | ord-ae48f2b10b344cca9a387f5399d2c103 |
| Source note | uspto-grants-2013_03 |